Karmanos Cancer Institute

Karmanos Cancer Institute receives 2024 Women's Choice Awards® for cancer care and patient experience

Retrieved on: 
Wednesday, December 20, 2023

DETROIT, Dec. 20, 2023 /PRNewswire/ -- The Barbara Ann Karmanos Cancer Institute has been named one of America's 2024 Best Hospitals for Cancer Care and one of the country's 100 Best Hospitals for Patient Experience by the Women's Choice Award®, America's trusted referral source for the best in health care. This is the 11th consecutive year Karmanos has been recognized by the Women's Choice Award® since the inception of the national list.

Key Points: 
  • DETROIT, Dec. 20, 2023 /PRNewswire/ -- The Barbara Ann Karmanos Cancer Institute has been named one of America's 2024 Best Hospitals for Cancer Care and one of the country's 100 Best Hospitals for Patient Experience by the Women's Choice Award® , America's trusted referral source for the best in health care.
  • "Every single staff member at Karmanos is dedicated to providing the best cancer care and experience for every patient, and this designation shows we're on the right track."
  • Delia Passi, founder and CEO of the Women's Choice Award® and a breast cancer survivor, emphasized that Karmanos and all 2024 Best Hospitals for Cancer Care deliver the most important care to women.
  • The Women's Choice Award® recognizes the Barbara Ann Karmanos Cancer Institute as one of the 100 Best Hospitals for Patient Experience in the U.S.

Karmanos welcomes new VP of the Karmanos Cancer Network

Retrieved on: 
Tuesday, December 5, 2023

DETROIT, Dec. 5, 2023 /PRNewswire/ -- The Barbara Ann Karmanos Cancer Institute has appointed Doris Ranski-Zazula, RN, MSA, as the vice president of the Karmanos Cancer Network, part of McLaren Health Care. The Karmanos Cancer Network is one of the largest cancer care and research networks in the United States, with 15 locations anchored by the Karmanos Cancer Institute freestanding cancer hospital headquartered in Detroit.   

Key Points: 
  • DETROIT, Dec. 5, 2023 /PRNewswire/ -- The Barbara Ann Karmanos Cancer Institute has appointed Doris Ranski-Zazula, RN, MSA, as the vice president of the Karmanos Cancer Network , part of McLaren Health Care.
  • The Karmanos Cancer Network is one of the largest cancer care and research networks in the United States, with 15 locations anchored by the Karmanos Cancer Institute freestanding cancer hospital headquartered in Detroit.
  • Ranski-Zazula transitioned to this position, having been the regional director of Cancer Services for Karmanos locations in Flint, Pontiac and Lapeer.
  • Ranski-Zazula will report to Brian Gamble, president of the Karmanos Cancer Hospital and Network.

Stage IV lung cancer survivor, disparities cancer researcher, family physician appointed as Karmanos' new associate center director

Retrieved on: 
Tuesday, November 28, 2023

DETROIT, Nov. 28, 2023 /PRNewswire/ -- The Barbara Ann Karmanos Cancer Institute welcomes Morhaf Al Achkar, M.D., Ph.D., MSCR, FAAFP, as the associate center director for Education. Dr. Al Achkar brings over 10 years of experience in education and teaching, research, and clinical family. He also brings valuable personal experience to his new role as a seven-year stage IV lung cancer survivor.

Key Points: 
  • He also brings valuable personal experience to his new role as a seven-year stage IV lung cancer survivor.
  • My responsibilities at Karmanos center around advancing education and training initiatives for the cancer center community.
  • Additionally, I am deeply passionate about enhancing the cancer care experience for our patients and addressing health disparities."
  • Additionally, Dr. Al Achkar has spent five years as an attending family medicine physician and assistant professor at Indiana University.

Karmanos Cancer Institute first to receive new FDA-approved treatment for advanced liver cancer

Retrieved on: 
Monday, November 13, 2023

DETROIT, Nov. 13, 2023 /PRNewswire/ -- Karmanos Cancer Institute, the largest provider of cancer care and research in Michigan and part of McLaren Health Care, announced today that it will be the first provider in the country to offer patients the new FDA-approved TheraBionic P1 device for the treatment of advanced hepatocellular carcinoma (HCC), the most common type of liver cancer. HCC accounts for approximately 90% of all liver cancers, with average survival rates between 6 and 20 months. The innovative TheraBionic P1 device is a novel at-home treatment that emits low levels of radio-frequency electromagnetic fields that block the growth of tumor cells without affecting healthy tissue. The device is approved for treating patients 18 years of age or older who fail first- and second-line therapies.

Key Points: 
  • HCC accounts for approximately 90% of all liver cancers, with average survival rates between 6 and 20 months.
  • The innovative TheraBionic P1 device is a novel at-home treatment that emits low levels of radio-frequency electromagnetic fields that block the growth of tumor cells without affecting healthy tissue.
  • The device is approved for treating patients 18 years of age or older who fail first- and second-line therapies.
  • "Often, patients with advanced hepatocellular carcinoma who fail first- and second-line therapies have severely impaired liver function, so additional treatment options are limited or nonexistent.

Dynami Funds New Groundbreaking Research for Lobular Breast Cancer

Retrieved on: 
Wednesday, November 1, 2023

DETROIT, Nov. 1, 2023 /PRNewswire/ -- The Dynami Foundation has funded groundbreaking new research and support for lobular breast cancer through their partnership with University of Michigan Health. Recently released University of Michigan Health Impact Report outlines the progress and work made possible by the Dynami Foundation's initiatives that are focused on transforming the future of invasive lobular breast cancer (ILC) through the funding of research.

Key Points: 
  • DETROIT, Nov. 1, 2023 /PRNewswire/ -- The Dynami Foundation has funded groundbreaking new research and support for lobular breast cancer through their partnership with University of Michigan Health.
  • From groundbreaking new research on circulating cells to a dual-institution effort to combat cancer, Dynami and University of Michigan have partnered to drive progress.
  • A patient-centered decision-making process by understanding goals of lobular breast cancer patients for an elevated, personalized breast reconstruction experience led by Dr. Paige Myers.
  • Dynami has funded over 12 research projects and will continue to fight for advancement for lobular breast cancer just like the incredible work and impact that we've made here."

Cancer Support Community’s New Short Documentary Film Named Official Selection at CINEHEALTH International Health and Wellness Film and Video Festival

Retrieved on: 
Wednesday, August 30, 2023

has been named an Official Selection of the inaugural CINEHEALTH International Health and Wellness Film and Video Festival (CINEHEALTH).

Key Points: 
  • has been named an Official Selection of the inaugural CINEHEALTH International Health and Wellness Film and Video Festival (CINEHEALTH).
  • The six-part short documentary film series explores historical and current injustices, and provides education about cancer clinical trials, the personal benefits of participation, effective community-based approaches, and strategies for achieving inclusive, quality cancer care, which includes access to clinical trials.
  • CINEHEALTH is the first and only international film festival focusing exclusively on health and wellness.
  • go to: https://www.cancersupportcommunity.org/healthequity#justified-medical-mi...
    For more information about Cancer Support Community’s health equity initiatives, including the Justified Medical Mistrust short documentary series and the Peer Clinical Trials Support Program, go to CSC’s Health Equity in Action page: https://www.cancersupportcommunity.org/healthequity
    For more information about CINEHEALTH: https://www.cine-health.com/

Mammotome Launches the HydroMARK™ Plus Breast Biopsy Site Marker, an Innovation for Tissue Marker Displacement

Retrieved on: 
Monday, August 21, 2023

CINCINNATI, Aug. 21, 2023 /PRNewswire/ -- Mammotome announced the launch of an innovative new HydroMARK™ Plus Breast Biopsy Site Marker designed to enhance ultrasound visibility, improve ease of locating, and mitigate displacement during surgical procedures.1,2,3,4 This device marks another great investment to the HydroMARK™ tissue marker portfolio, one of the top-selling breast biopsy marker brands in the world.5

Key Points: 
  • CINCINNATI, Aug. 21, 2023 /PRNewswire/ -- Mammotome announced the launch of an innovative new HydroMARK™ Plus Breast Biopsy Site Marker designed to enhance ultrasound visibility, improve ease of locating, and mitigate displacement during surgical procedures.1,2,3,4 This device marks another great investment to the HydroMARK™ tissue marker portfolio, one of the top-selling breast biopsy marker brands in the world.5
    "I am excited for this innovative biopsy marker to come to market," said Radiologist Dr. Evita Singh, Director of Breast Imaging at Karmanos Cancer Institute.
  • "After seeing the tabletop test on the HydroMARK™ Plus Breast Biopsy Site Marker, I look forward to having a solution that addresses the need for a nickel-free, long-term, ultrasound visible clip that will not displace for the surgeons."
  • The HydroMARK™ Plus marker offers the same unmatched benefits as the original HydroMARK™ marker portfolio, which features exclusive hydrogel technology.
  • The HydroMARK™ Plus Breast Biopsy Site Marker will be available to clinicians in the United States by the end of 2023 with plans to expand to Canada and other select countries across the globe.

Mammotome Launches the HydroMARK™ Plus Breast Biopsy Site Marker, an Innovation for Tissue Marker Displacement

Retrieved on: 
Monday, August 21, 2023

CINCINNATI, Aug. 21, 2023 /PRNewswire/ -- Mammotome announced the launch of an innovative new HydroMARK™ Plus Breast Biopsy Site Marker designed to enhance ultrasound visibility, improve ease of locating, and mitigate displacement during surgical procedures.1,2,3,4 This device marks another great investment to the HydroMARK™ tissue marker portfolio, one of the top-selling breast biopsy marker brands in the world.5

Key Points: 
  • CINCINNATI, Aug. 21, 2023 /PRNewswire/ -- Mammotome announced the launch of an innovative new HydroMARK™ Plus Breast Biopsy Site Marker designed to enhance ultrasound visibility, improve ease of locating, and mitigate displacement during surgical procedures.1,2,3,4 This device marks another great investment to the HydroMARK™ tissue marker portfolio, one of the top-selling breast biopsy marker brands in the world.5
    "I am excited for this innovative biopsy marker to come to market," said Radiologist Dr. Evita Singh, Director of Breast Imaging at Karmanos Cancer Institute.
  • "After seeing the tabletop test on the HydroMARK™ Plus Breast Biopsy Site Marker, I look forward to having a solution that addresses the need for a nickel-free, long-term, ultrasound visible clip that will not displace for the surgeons."
  • The HydroMARK™ Plus marker offers the same unmatched benefits as the original HydroMARK™ marker portfolio, which features exclusive hydrogel technology.
  • The HydroMARK™ Plus Breast Biopsy Site Marker will be available to clinicians in the United States by the end of 2023 with plans to expand to Canada and other select countries across the globe.

KSP, McLaren's Specialty Pharmacy, earns full URAC re-accreditation

Retrieved on: 
Tuesday, August 1, 2023

DETROIT, Aug. 1, 2023 /PRNewswire/ -- KSP, McLaren Health Care's Specialty Pharmacy, has earned full re-accreditation for specialty pharmacy from URAC through August 1, 2026. By achieving this status, KSP has demonstrated its commitment to quality care, enhanced process, patient safety and improved outcomes.

Key Points: 
  • DETROIT, Aug. 1, 2023 /PRNewswire/ -- KSP , McLaren Health Care's Specialty Pharmacy, has earned full re-accreditation for specialty pharmacy from URAC through August 1, 2026.
  • By achieving this status, KSP has demonstrated its commitment to quality care, enhanced process, patient safety and improved outcomes.
  • With this designation, KSP will continue providing specialty agents for various diseases.
  • URAC congratulates KSP on their achievement of Specialty Pharmacy Accreditation.

D'Ambrosio joins Barbara Ann Karmanos Cancer Institute as Chief Development Officer

Retrieved on: 
Monday, July 17, 2023

DETROIT, July 17, 2023 /PRNewswire/ -- The Barbara Ann Karmanos Cancer Institute welcomes Arnold D'Ambrosio as the new Chief Development Officer (CDO), effective Monday, July 10, 2023. D'Ambrosio, a Detroit native, brings the National Cancer Institute-designated comprehensive cancer center over 30 years of donor relations, fundraising and major gifts experience, with over a decade of that time in mission-driven healthcare giving.

Key Points: 
  • DETROIT, July 17, 2023 /PRNewswire/ -- The Barbara Ann Karmanos Cancer Institute welcomes Arnold D'Ambrosio as the new Chief Development Officer (CDO), effective Monday, July 10, 2023.
  • He will provide leadership, oversight, and philanthropic stewardship and manage the day-to-day operations of the Karmanos Development Department.
  • To effectively cultivate and generate philanthropic support for the Karmanos Cancer Foundation , Karmanos Cancer Institute and Karmanos Cancer Hospital.
  • He will report directly to the president and CEO of the Barbara Ann Karmanos Cancer Institute and provide continuing support to the Foundation's board of directors.